Latest News

In an important follow-up to LEAP-On, which demonstrated that the early introduction of peanut in high-risk infants led to durable prevention of peanut allergy, the investigators now show that early consumption of peanut in infants at high risk of peanut allergy is allergen-specific and does not prevent the development of other allergic disease to other foods, aeroallergens, or allergic reactions to tree nuts and sesame. Furthermore, peanut consumption does not hasten the resolution of eczema or egg allergy.

An article published today in the American Journal of Transplantation examined the prevalence of a previously identified genetic signature associated with tolerance in a cohort of kidney transplant patients who may benefit from immunosuppression minimization. A transplant recipients’ lifetime use of immunosuppressive drugs to prevent rejection exposes them to health complications associated with drug toxicity and long-term immunosuppression.

In a study appearing online in Neurology, the HALT-MS trial demonstrated that patients with active relapsing-remitting multiple sclerosis (RRMS) showed sustained remission out to 5 years following high dose immunosuppressive therapy combined with autologous hematopoietic cell transplantation (HDIT/HCT).HALT-MS is a phase II clinical trial of HDIT/HCT for patients with RRMS who experienced relapses with loss of neurological function while on MS disease modifying therapy (DMT).

An expert panel sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, issued clinical guidelines to aid health care providers in early introduction of peanut-containing foods to infants to prevent the development of peanut allergy.Peanut allergy is a growing health problem for which no treatment or cure exists.